Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Unknown 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Endometrial Neoplasms 4Anorexia 3Weight Loss 2Cachexia 2Body Weight 2Squamous Intraepithelial Lesions 1Recurrence 1Pancreatic Neoplasms 1Overweight 1Obesity 1Neoplasms 1Lung Neoplasms 1Infertility 1Breast Neoplasms 1Body Weight Changes 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Megestrol Acetate × Clear all
NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Emory University

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡